COMP <GO>
REGN vs MRK // REVENUE GROWTH (YOY)
Regeneron Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: REGN 7
— MRK 8
▲ REVENUE GROWTH (YOY) LEADER: MRK
LAST: $927.89 (+13.33%) • MKT CAP: $84.30B
revenue-growth
1.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
revenue-growth
1.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (REGN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | REGN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 20.70% | -11.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.2x | 15.3x | +4.90 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 5.14% | 3.42% | +1.72 | REGN | /fcf-yield <GO> |
| Operating Margin | 24.90% | 34.30% | -9.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 31.40% | 28.10% | +3.30 | REGN | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 1.00% | 1.30% | -0.30 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.44% | 2.26% | -1.82 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.72 | 5.19 | +2.53 | REGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | REGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.60% | +0.80 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 79.1 | 56.9 | +22.25 | REGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 0.92 | +0.24 | REGN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 18.4x | -1.00 | REGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $84.30B | $361.02B | -$276.72B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | REGN REV | MRK REV | REGN GROSS % | MRK GROSS % | REGN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.34B | $65.01B | 44.0% | 74.8% | $4.33B | $12.36B |
| FY 2024 | $14.20B | $64.17B | 44.0% | 76.3% | $3.78B | $18.10B |
| FY 2023 | $13.12B | $60.12B | 44.0% | 44.0% | $4.00B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
REGN // BETA 1.16
MRK // BETA 0.92